Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Bluebird Bio has agreed to sell itself to private equity firms Carlyle and SK Capital for $29 million to stabilize its gene therapy commercialization efforts.
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Bluebird Bio has agreed to sell itself to private equity firms Carlyle and SK Capital for $29 million to stabilize its gene therapy commercialization efforts.
Carl H. June, creator of CAR-T therapies: The genetic medicine of the future will be able to treat everything, from diabetes to chronic infections'
Carl H. June envisions a future in medicine led by personalized gene therapies that can cure numerous diseases, including cancers and chronic conditions.
World's first personalized CRISPR therapy given to baby with genetic disease
CRISPR therapy shows promise for treating ultra-rare genetic diseases, demonstrated by KJ Muldoon, the first recipient of tailored gene-editing treatment.
Carl H. June, creator of CAR-T therapies: The genetic medicine of the future will be able to treat everything, from diabetes to chronic infections'
Carl H. June envisions a future in medicine led by personalized gene therapies that can cure numerous diseases, including cancers and chronic conditions.
World's first personalized CRISPR therapy given to baby with genetic disease
CRISPR therapy shows promise for treating ultra-rare genetic diseases, demonstrated by KJ Muldoon, the first recipient of tailored gene-editing treatment.
In a World First, CRISPR Drug Tailored for One Baby Shows Life-Saving Promise
CRISPR technology successfully healed a newborn with a rare genetic disorder, indicating a breakthrough in personalized gene therapy for genetic diseases.
In a World First, CRISPR Drug Tailored for One Baby Shows Life-Saving Promise
CRISPR technology successfully healed a newborn with a rare genetic disorder, indicating a breakthrough in personalized gene therapy for genetic diseases.
Uncovering New Therapeutic Targets for Pediatric Epilepsy - News Center
Researchers have identified new mechanisms in Dravet syndrome that highlight novel therapeutic targets, particularly in intronic regions of the SCN1A gene.
Doctors in London cure blindness in children with rare condition
Doctors in London have pioneered gene therapy to cure childhood blindness caused by a genetic condition, marking a significant advancement in medical science.
Doctors in London cure blindness in children with rare condition
Doctors in London have pioneered gene therapy to cure childhood blindness caused by a genetic condition, marking a significant advancement in medical science.
The search for solutions to geographic atrophy of the retina
Age-related macular degeneration (AMD) leads to progressive vision loss, significantly impacting independence, but recent drug approvals offer hope for treatment.
Goldman Sachs Recommends These 3 Growth Stocks As Strong Buys in September
Goldman Sachs identifies three compelling growth stocks worth considering, signaling a shift towards diverse sectors amidst a technology market rotation.